Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial (Q40342385)

19 September 2017

Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial (English)

1 reference

19 September 2017

phase I clinical trial

0 references

0 references

0 references

3

Timothy Burgess

1 reference

19 September 2017

1

Charmagne G Beckett

1 reference

19 September 2017

8

Peifang Sun

1 reference

19 September 2017

9

Tadeusz Kochel

1 reference

19 September 2017

Kanakatte Raviprakash

10

object named as

Kanakatte Raviprakash

1 reference

19 September 2017

4

Janine R Danko

1 reference

19 September 2017

6

Monika Simmons

1 reference

19 September 2017

Jeffrey Tjaden

2

1 reference

19 September 2017

Cindy Tamminga

5

1 reference

19 September 2017

Shuenn-Jue Wu

7

1 reference

19 September 2017

Curtis G Hayes

11

1 reference

19 September 2017

Kevin R Porter

12

1 reference

19 September 2017

language of work or name

English

0 references

publication date

25 November 2010

1 reference

19 September 2017

1 reference

19 September 2017

29

1 reference

19 September 2017

5

1 reference

19 September 2017

960-968

1 reference

Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.

19 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.050

Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.050

Construction and biological properties of yellow fever 17D/dengue type 1 recombinant virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.050

Formalin-inactivated whole virus and recombinant subunit flavivirus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.050

Phase 1 Trial of the Dengue Virus Type 4 Vaccine Candidate rDEN4 30-4995 in Healthy Adult Volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.050

Evaluation of immunity and protective efficacy of a dengue-3 pre-membrane and envelope DNA vaccine in Aotus nancymae monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.050

Dengue 2 PreM-E/LAMP chimera targeted to the MHC class II compartment elicits long-lasting neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.050

Needle-free Biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM-CSF gene increases immunogenicity and protection from virus challenge in Aotus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.050

Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.050

A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.050

Characterization of Antibody Responses to Combinations of a Dengue Virus Type 2 DNA Vaccine and Two Dengue Virus Type 2 Protein Vaccines in Rhesus Macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.050

Differential effects of dengue virus on infected and bystander dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.050

Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.050

Cutting Edge: Long-Term B Cell Memory in Humans after Smallpox Vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.050

A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.050

DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.050

A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.050

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.050

A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.050

Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.050

Introduction to DNA vaccines – Las Vegas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.050

10.1016/J.VACCINE.2010.11.050

7 January 2021

Identifiers

DOI

1 reference

19 September 2017

1 reference